Press Releases

Sign up for Email Alerts Press Release RSS

06/03/2019
Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab)
Term:Corporate/Financial News
Language:English
06/03/2019
Bristol-Myers Squibb Announces First Presentation of Results for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination in Advanced Hepatocellular Carcinoma at ASCO 2019
Term:BMS
Language:English
05/24/2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Term:Corporate/Financial News
Language:English
05/16/2019
Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019
Term:Corporate/Financial News
Language:English
05/14/2019
Award-Winning Actor and Producer Sterling K. Brown Joins Bristol-Myers Squibb in Effort to Share Stories of What It’s Like to Live with Cancer Today
Term:Corporate/Financial News
Language:English
05/14/2019
Bristol-Myers Squibb to Take Part in the UBS Global Healthcare Conference
Term:Squibb
Language:English
05/09/2019
Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
Term:Corporate/Financial News
Language:English
05/08/2019
Bristol-Myers Squibb Company Prices $19 Billion of Senior Unsecured Notes
Term:Corporate/Financial News
Language:English
05/01/2019
Bristol-Myers Squibb Company Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Celgene Corporation Notes
Term:Corporate/Financial News
Language:English
05/01/2019
Bristol-Myers Squibb Company Announces Launch of Private Offering of Senior Unsecured Notes
Term:Corporate/Financial News
Language:English

Business Wire NewsHQ^sm